CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ADVL1515 | COG | A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors | Pediatric CIRB | Completed |
| ADVL1412 | COG | A Phase 1/2 Study of Nivolumab (IND# 124729) in Children; Adolescents; and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab | Pediatric CIRB | Completed |
| ANBL0931 | COG | A Comprehensive Safety Trial of Chimeric Antibody 14.18 (ch14.18) with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy | Pediatric CIRB | Completed |
| ACNS2031 | COG | A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features | Pediatric CIRB | Available to Open |
| AALL0622 | COG | Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969; NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase II/III Study | Pediatric CIRB | Completed |
| AHOD03P1 | COG | Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD): A Groupwide Pilot Study | Pediatric CIRB | Available to Open |
| APEC1621-MASTER | COG | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Study | Pediatric CIRB | Available to Open |
| AALL03B1 | COG | Classification of Acute Lymphoblastic Leukemia | Pediatric CIRB | Completed |
| ACCL0934 | COG | A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Groupwide Phase III Study | Pediatric CIRB | Completed |
| AOST1321 | COG | Phase II Study of Denosumab (IND #127430; NSC# 744010); a RANK Ligand Antibody; for Recurrent or Refractory Osteosarcoma | Pediatric CIRB | Available to Open |